Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromethylthionine mesylate (LMTM) monotherapy in Alzheimer's disease
2017-003558-17Phase 3Unknown
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromethylthionine mesylate in Alzheimer's disease (AD) (3 arms), sponsored by TauRx Therapeutics Ltd. Primary endpoints: Annualized rate of whole brain atrophy over 52 weeks and Primary efficacy endpoints for double-blind treatment period. Status: unknown.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-003558-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003558-17.